CION Ameerpet
TARGETED AND HORMONE THERAPY FOR BREAST CANCER AT CION
Targeted & Hormone Therapy for Breast Cancer — Precision Treatment at CION Hyderabad
Targeted and hormone therapies treat breast cancer by acting on the specific biology of your tumour — HER2 receptors, oestrogen receptors, or progesterone receptors. CION's medical oncologists prescribe the therapy matched to your biopsy report, reviewed by the full tumour board before treatment begins.
- HER2-targeted therapy for HER2-positive breast cancer
- Hormone therapy (5-year course) for oestrogen/progesterone receptor-positive cancers
- Tumour board review — your plan agreed by medical, surgical and radiation oncologists
- Free first consultation — ₹950 waived, including written cost estimate
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Did you know?
Most breast cancers express one or more receptors that targeted or hormone therapies act on. Your biopsy report's ER, PR, and HER2 status determines which therapies are appropriate. Receptor-positive cancers treated with matched therapy have meaningfully better outcomes than those treated without it. Source: NCCN Breast Cancer Guidelines.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Types of Therapy
Types of Targeted and Hormone Therapy for Breast Cancer
Your biopsy report's ER, PR, and HER2 receptor status determines which therapies apply. CION's medical oncologists and tumour board match your plan to what your specific tumour expresses — not to a default protocol.
Note: Your oncologist and tumour board prescribe the specific agent and dose after reviewing your biopsy receptor status. Therapy categories below are for awareness only.
HER2-Positive Cancers
HER2-Targeted Therapy
For cancers that over-express the HER2 protein. These agents attach to HER2 receptors and block the signals that drive tumour growth. Typically given as day-care infusions, often alongside chemotherapy, for a defined number of cycles. Indicated only when biopsy confirms HER2-positive status.
Pre-Menopausal · ER+
Hormone Therapy
For oestrogen receptor-positive (ER+) breast cancers in pre-menopausal women. Agents block oestrogen from binding to cancer cells, slowing growth. Taken as a daily oral tablet at home — typically for a 5–10 year course. Duration and agent decided by your oncologist based on stage and risk.
Post-Menopausal · ER+
Hormone Therapy — Aromatase Inhibitors
For ER-positive cancers in post-menopausal women. Lower oestrogen levels by blocking the enzyme that converts other hormones to oestrogen. Taken as a daily oral tablet at home for a 5-year course. Commonly prescribed after surgery to reduce recurrence risk.
Advanced HR+ Cancers
CDK4/6 Inhibitors
For advanced hormone receptor-positive (HR+) breast cancers. Target proteins that regulate cell division, slowing cancer progression when combined with hormone therapy. Usually prescribed for metastatic or recurrent HR+/HER2-negative disease. Taken orally at home on a cyclical schedule.
Triple-Negative · Advanced
Immunotherapy / Checkpoint Inhibitors
For advanced or metastatic triple-negative breast cancers (TNBC) expressing certain markers. Checkpoint inhibitors help the immune system recognise and attack cancer cells. Given as day-care infusions. Indicated only in specific advanced TNBC settings — eligibility confirmed from biopsy and staging.
BRCA+ · Advanced
PARP Inhibitors
For BRCA1/2-positive advanced breast cancers. PARP inhibitors block a DNA-repair pathway that cancer cells with BRCA mutations rely on. Taken as oral tablets at home. Eligibility requires confirmed BRCA-positive genetic testing alongside biopsy review.
How Your Plan Is Made
How Does CION Decide Your Therapy Plan?
Targeted and hormone therapies only work for the right receptor type. At CION, therapy is prescribed only after biopsy receptor confirmation — never on assumption, never on a default protocol.
1
Biopsy receptor status is read
Your pathology report's ER, PR, and HER2 results are reviewed by CION's medical oncologist. If the biopsy has not yet been done, your oncologist guides you on the appropriate test before any therapy discussion.
2
Tumour board reviews your case
Medical, surgical and radiation oncologists review your biopsy, staging, and overall health together. The tumour board ensures the systemic therapy recommendation fits the full picture — not just the receptor type in isolation.
3
Therapy category is matched
HER2+ results lead to HER2-targeted agents. ER/PR+ results lead to hormone therapy. Triple-negative with advanced disease leads to chemotherapy and, where appropriate, immunotherapy or PARP inhibitors if BRCA-positive. The receptor result is the deciding factor.
4
Plan agreed and explained to you
Your oncologist explains the agreed plan in plain language — why this therapy, how it is given, what to expect, and what the alternatives are. You have time to ask every question before any decision is made.
5
Free written cost estimate
Before any treatment begins, you receive a written estimate — drug cost at MRP plus CION service fee, number of cycles, and expected schedule. Insurance pre-authorisation is handled by the admissions team on your behalf.
6
Treatment begins — with ongoing monitoring
Day-care infusions are supervised in CION's dedicated infusion units. Oral therapy is monitored through regular follow-up consultations. If response or receptor status changes, the tumour board reviews and revises the plan.
Patient Outcomes
Why Matched Therapy at CION Makes a Difference
Tumour-board reviewed, receptor-matched therapy is one of the reasons CION's 1-year breast cancer survival is above the national average. At a population level, the difference is meaningful.
96.9%
1-year breast cancer survival at CION*
85.4%
National average*
+11.5%
Higher survival vs national avg
*1-year observed survival; source: ICMR National Cancer Registry Programme (NCRP). Individual outcomes vary by stage, biology and overall health.
These numbers represent population-level data, not individual guarantees. What they reflect is consistent, evidence-based care — a tumour board on every case, receptor-matched therapy plans, and NCCN-aligned protocols applied to every patient.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Treatment Matched to Your Biology — Not a Protocol for Everyone
Targeted and hormone therapies only work for the right receptor type. CION's medical oncologists confirm your biopsy receptor status before prescribing — and the tumour board reviews every plan before treatment starts.
What Patients Ask
Targeted and Hormone Therapy — What Patients Ask
The most common practical questions from patients who have been told they need targeted or hormone therapy — answered plainly.
How do I know which therapy is right for my breast cancer?
Your biopsy report's receptor status (ER, PR, HER2) is the deciding factor. HER2-positive cancers receive HER2-targeted agents. Hormone receptor-positive (ER/PR+) cancers receive hormone therapy. Triple-negative cancers — where all three receptors are absent — typically receive chemotherapy and, in advanced cases, immunotherapy or PARP inhibitors if BRCA-positive.
CION's tumour board reviews your biopsy before any systemic therapy is prescribed. If your report does not include receptor status, your oncologist will advise on the appropriate additional testing.
How long does hormone therapy last?
Hormone therapy for receptor-positive breast cancer is typically prescribed for 5–10 years. post-menopausal women are usually prescribed aromatase inhibitors. Your oncologist decides the duration based on your stage, risk profile, and menopausal status.
The indicative 5-year course cost at CION is ₹1.8L–6L, depending on the specific agent prescribed. A written estimate is provided before any therapy begins.
Does HER2-targeted therapy require hospital admission?
No. HER2-targeted agents are administered as day-care infusions at CION's dedicated infusion units — you come in for the session and go home the same day. No overnight admission is required for most cases. Some newer agents are available as subcutaneous injections, which are faster to administer.
The number of cycles and the interval between infusions (typically every 3 weeks) are specified in your treatment plan.
What are the indicative costs of targeted therapy?
The indicative full-course cost of HER2-targeted therapy is ₹5L–18L, depending on the specific agent and whether it is given alongside chemotherapy. Drug costs are set by pharmaceutical pricing (MRP) — CION adds a transparent service fee itemised in your written estimate.
CION accepts major health insurance plans, Aarogyasri, CGHS, ECHS, and ESI. The admissions team checks coverage and handles pre-authorisation on your behalf.
Can I continue hormone therapy at home?
Yes. Most oral hormone therapy agents — aromatase inhibitors — are taken as daily tablets at home. CION's oncologist prescribes and monitors your therapy with regular scheduled follow-up consultations, reviewing response and managing side effects at each visit.
Many patients find this one of the practical advantages of hormone therapy — clinic visits are for monitoring, not daily or weekly infusions.
Will my therapy plan change if my biopsy is updated?
Yes. If a repeat biopsy or updated pathology report shows a change in receptor status — for example, if a tumour loses HER2 expression — your tumour board will review the updated result and revise your therapy plan accordingly. Therapy is always matched to current biopsy evidence.
If you are bringing a biopsy report from another hospital, CION's oncologist reviews it and the tumour board confirms whether your prescribed plan matches your receptor biology before you commit to starting treatment.
Your Therapy Journey
Your Targeted / Hormone Therapy Journey at CION
From biopsy report review to ongoing monitoring — here is the sequence every patient goes through when starting targeted or hormone therapy at CION.
1
Biopsy report review
Bring your biopsy pathology report — including ER, PR, and HER2 receptor results — to your first consultation. If receptor status has not been tested, your oncologist advises on the appropriate additional testing before proceeding.
2
Tumour board agrees your therapy plan
Medical, surgical and radiation oncologists review your case together. The therapy category is matched to your receptor status, stage, and overall health — the agreed plan is explained to you before any treatment commitment is made.
3
Free written cost estimate
You receive a written estimate itemising drug cost at MRP plus CION service fee, number of cycles or duration of oral therapy, and expected schedule. Insurance pre-authorisation is initiated by the admissions team on your behalf.
4
Therapy begins — day-care infusion or oral at home
HER2-targeted agents and immunotherapy are administered as supervised day-care infusions at CION's infusion units. Hormone therapy agents and CDK4/6 inhibitors are taken as oral tablets at home on the prescribed schedule.
5
Ongoing monitoring and plan review
Regular follow-up consultations track response, manage side effects, and monitor for changes in your condition. If a repeat biopsy changes your receptor status, the tumour board reviews and revises the plan accordingly.
15,000+ Patients Have Chosen CION
Patients on Targeted and Hormone Therapy — Their Experiences.
Hear from HER2-positive and receptor-positive breast cancer patients who received matched targeted and hormone therapy at CION — and valued the clear explanation of why their specific plan was chosen.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Targeted & Hormone Therapy for Breast Cancer — Your Questions
How do I know which targeted or hormone therapy is right for my breast cancer?
Your biopsy report's receptor status (ER, PR, HER2) determines which therapies are appropriate. HER2-positive cancers receive HER2-targeted agents. Hormone receptor-positive (ER/PR+) cancers receive hormone therapy (aromatase inhibitors). Triple-negative cancers typically use chemotherapy and, in advanced cases, immunotherapy or PARP inhibitors if BRCA-positive. CION's tumour board reviews your biopsy before any systemic therapy is prescribed.
How long does hormone therapy for breast cancer last?
Hormone therapy for receptor-positive breast cancer is typically prescribed for 5–10 years. Aromatase inhibitors are used post-menopause. Your oncologist decides the duration based on your stage, receptor status, and risk profile. The indicative 5-year course cost is ₹1.8L–6L at CION (depending on the specific agent).
Is HER2-targeted therapy given as day-care infusion or oral medication?
Most HER2-targeted agents are given as intravenous infusions in the day-care unit — typically every 3 weeks for 12–18 cycles. Some newer agents are available as subcutaneous injections, which are faster. Your oncologist will specify the administration route for your prescribed agent.
What is the indicative cost of HER2-targeted therapy at CION?
The indicative full-course cost of HER2-targeted therapy is ₹5L–18L, depending on the specific agent prescribed and whether it is given alongside chemotherapy. Drug costs are set by pharmaceutical pricing. A free written estimate is provided before your first cycle, itemising drug cost at MRP plus the CION service fee.
Can I take hormone therapy at home between consultations?
Yes. Most oral hormone therapy agents (aromatase inhibitors) are taken daily as tablets at home. CION's oncologist prescribes and monitors your therapy, with regular follow-up consultations to assess response, manage side effects, and adjust the plan if needed.
What happens if my biopsy receptor status changes after initial testing?
If a repeat biopsy or updated pathology report shows a change in receptor status — for example, if a tumour loses HER2 expression — your tumour board will review the updated result and revise your therapy plan accordingly. Therapy is always matched to current biopsy evidence.
Is the first consultation for targeted or hormone therapy free?
Yes. The first consultation is free — the ₹950 usual fee is waived for all cancer patients. Your oncologist reviews your biopsy receptor status, the tumour board agrees your therapy plan, and you receive a free written cost estimate before any treatment begins.
Does CION accept insurance for targeted and hormone therapy?
Yes. CION accepts major health insurance plans, Aarogyasri, CGHS, ECHS and ESI. Coverage of HER2-targeted agents varies by plan; the admissions team will check your specific coverage and handle pre-authorisation from your first consultation. Drug costs are billed at MRP.
The information on this page is for general awareness only and is not a substitute for professional medical advice, diagnosis, or treatment. Treatment options, costs, and outcomes vary — all figures are indicative. Please consult a qualified oncologist about your individual condition.
*1-year observed survival; source: ICMR National Cancer Registry Programme (NCRP).